Thymalin Research Guide: Thymic Fraction Identity and Evidence Limits

A Thymalin research guide has to begin with a category correction: “thymalin peptide” is a common search phrase, but the material is a fraction. That changes what sequence, molecular weight, purity, mass spectrometry, replication, and even “same material” can mean. It also separates Thymalin from thymulin, thymosin alpha 1, thymopentin, and other similarly named thymic materials.

Research boundary: The Apex material is a research-grade lyophilized reagent for in-vitro and preclinical research only. It is not a pharmaceutical, is not for human consumption, and this page provides no preparation, administration, treatment, or combined-use protocol. Human literature is reviewed as historical evidence, not converted into instructions.

What Is Thymalin?

Thymalin, also indexed as Timalin in parts of the Russian-language corpus, is described as a standardized polypeptide fraction extracted from bovine calf thymus. The current Thymalin product record describes a defined mixture dominated by short peptides, a component range of approximately 1–10 kDa, and Glu-Trp as a trace marker. It does not define one peptide.

Linkova et al. (2023), from the originating network, names KE (Lys-Glu) and EW (Glu-Trp) as active substances of Thymalin. That attribution does not turn the full fraction into two dipeptides. Sëmina et al. (1993) independently uses “thymogen (Glu-Trp),” supporting the name bridge. Bergeon et al. (2008) describes free Glu-Trp as highly hydrophilic with low membrane permeability—the premise for its conjugation experiments—which reinforces that results for the isolated dipeptide do not establish what the whole fraction does.

Thymalin, Thymulin, and Thymosin: Six Names That Are Not the Same Material

The most consequential name collision is thymulin. A PubChem record titled Nonathymulin (CID 3085284) describes the defined nonapeptide pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, formula C₃₃H₅₄N₁₂O₁₅, molecular weight 858.9 g/mol, and CAS 63958-90-7; its synonym list includes “Thymalin.” PubChem’s separate name lookup for thymulin resolves to CID 71300623, which carries the same formula and mass but a different CAS record. That collision is why an approximate 858 Da value has propagated into catalog lines and secondary summaries for a material that has no single mass.

Two additional search traps matter. “Thymogen” usually refers to Glu-Trp rather than the whole fraction. Some papers use “thymalin” for an endogenous immunoreactive substance in tissue rather than an administered preparation; Khlystova et al. (2002) is one such example. Naive term counts therefore overstate interventional evidence.

Where Thymalin Came From: Two Parallel Thymus-Extract Programs

The Western thymosin program and the program of Vladimir Khavinson and V.G. Morozov began with thymus-derived material but followed different identity strategies. Goldstein et al. (2004) reviews the chemistry and history of thymosins: calf-thymus fractions, thymosin fraction 5, and the eventual isolation of defined thymosin alpha 1. The program moved from mixture to characterized component.

That second program is now centered on the Saint Petersburg Institute of Bioregulation and Gerontology, the affiliation carried by many of the records cited here, and produced a family of tissue-derived preparations including the pineal extract Epithalamin. The bibliographic record by Safronov et al. (1984) is the earliest English-language PubMed record with Thymalin in its title, not the first Thymalin record: Russian-language PubMed records with Thymalin in the title date to 1981. Here, the fraction remained the named preparation. Those histories should not be collapsed into one molecule or one product. The Epithalon guide covers the defined AEDG tetrapeptide; Epithalamin in historical co-administration reports was a pineal extract and is not the same material.

A useful analytical analogue comes from Hannappel et al. (2018). Re-evaluating thymosin fraction 5 with high-resolution mass spectrometry resolved more than 100 monoisotopic masses, including truncated species associated with preparation. The paper does not characterize Thymalin, but it demonstrates why a thymus fraction cannot be reduced to one molecular ion.

What the Experimental Record Shows

Khavinson et al. (2020) studied human hematopoietic stem cells in vitro. The abstract reports two- to three-fold reductions in CD44 and CD117 expression and a 6.8-fold increase in CD28, interpreted indirectly as differentiation toward mature T lymphocytes. It does not provide sample count, replicate count, statistical tests, or a clinical outcome.

Linkova et al. (2023) combined computational work with PBMC experiments from four human donors and reported 1.4- to 6.0-fold reductions in selected cytokine synthesis for Thymalin and KE/EW dipeptides. ACE2, CYSLTR1, CHUK, AKT1, and AKT2 portions of that paper are computational predictions. Four donors cannot establish a population-level effect.

Avolio et al. (2022), co-authored with the Saint Petersburg Institute of Bioregulation and Gerontology group, studied five peptide preparations in the human THP-1 monocytic line. Its abstract attributes inflammatory effects collectively, not as a Thymalin-specific magnitude. Other cell and tissue papers remain adjacent context: Ryzhak et al. (2015) examined tissue cell cultures from rats of different ages, while Caputi et al. (2019), also co-authored with the Saint Petersburg group, tested four defined short peptides including KE on human periodontal-ligament stem cells in vitro. The Caputi study did not test the Thymalin fraction. Defined short-peptide results do not automatically characterize the parent fraction.

Independent animal work is small but real. Zhukova et al. (2018) reported observations in rats with transplanted sarcoma 45; the abstract omits group sizes, controls, and statistics, so the result remains a screening-model observation rather than an anticancer conclusion. Two Ukrainian papers describe the same fully reported 48-rat, four-group design, with 12 WAG rats per arm—Boiko et al. (2024) on reparative osteogenesis and Boiko et al. (2024) on immune-cell expression. They state their design more completely than the other Thymalin primary studies in this pool, but they do not create two independent replications.

The Human Evidence and the Longevity Claim

Khavinson and Mikhalskiĭ (2003) reports follow-up of 266 elderly people over six to eight years and describes mortality ratios for groups receiving thymic or pineal preparations. The abstract does not report randomization, blinding, per-arm sample sizes, confidence intervals, or p-values. Its largest figure—a 4.1-fold decrease in mortality rate versus control—came from a separate arm receiving Thymalin together with Epithalamin, so it cannot be attributed to Thymalin alone.

Khavinson et al. (2021) describes directionally favorable COVID-19-related observations without enough quantitative design detail to produce an effect estimate. Kuznik et al. (2022) is more informative because it compares three non-randomized arms against an active comparator and reports arm-level outcome magnitudes. It is not independent of the originating network: Kuznik co-authored the 2021 report with Khavinson, and the final author, Linkova, is first author of the 2023 Saint Petersburg paper. The indexed English and Russian abstracts also disagree on hospital mortality for the Thymalin arm: 20.6% versus 16.2%. The discrepancy is documented; it is not evidence of misconduct and prevents use of one precise number without the full paper.

Older clinical literature includes Bakhidze et al. (1990) in endometrial-cancer patients. Its existence prevents a “no human reports” claim, but it does not establish a modern controlled evidence lane. No trial registration identifier for Thymalin was found in ClinicalTrials.gov, ISRCTN, or the EU Clinical Trials Register as of August 24, 2026. The EU CTIS public API, the Russian State Register of Medicines, and ChiCTR were not programmatically queryable in that pass, so no claim is made about them.

How Strong Is This Literature? A Structural Audit

A reproducible audit is more useful than saying the field is “controversial.” As of August 24, 2026, PubMed contained 126 records with Thymalin in the title; 116 were Russian-language and 81 predated 1990. That scope is deliberately narrow: English-language work also appears outside the title-only set, including Khavinson and Morozov’s 2003 longevity report, Khavinson and colleagues’ 2021 COVID-19 report, and the 2022 THP-1 study cited here.

The 2003 longevity report had six citing records in Europe PMC, four of them including Khavinson as an author. That is source concentration, not proof of error. Conversely, independent work from Rostov and Kyiv prevents the claim that every Thymalin paper comes from one institution. The correct conclusion is uneven independence: the literature around the largest human claims is highly concentrated, while smaller independent animal programs address different outcomes.

Wolf et al. (2011), a Cochrane review of purified thymus extracts in cancer care, found no evidence of survival or tumor-response benefit and judged most included trials at moderate or higher risk of bias. The same review reported preliminary class-level evidence that purified thymus extracts reduced severe infectious complications (RR 0.54, 95% CI 0.38–0.78). It assessed thymosin fraction 5 and thymostimulin, not Thymalin itself, so neither direction is a direct Thymalin result. Zeng et al. (2019) reported improved response rates and one-year survival when synthetic thymic peptides were added to chemotherapy, but the abstract names thymosin alpha 1 and rates the evidence from moderate to very low. Those results cannot be transferred to a tissue-derived fraction.

None of the 20 cited records is retracted or carries an expression of concern. The venues of the two most contested papers—Neuro Endocrinol Lett and Adv Gerontol—remain MEDLINE-indexed (NLM Catalog 8008373 and 100971443, checked August 24, 2026). The real limitations are source concentration and incomplete design reporting, not journal status.

What Analytical Documentation Can Verify

A fraction needs a batch-comparability framework. RP-HPLC can compare a chromatographic pattern with a qualified reference batch under the same method. High-resolution mass spectrometry can reveal many component-level ions and mixture complexity. Neither method turns the material into one molecule, and one detected marker cannot define the complete preparation.

• Reference fingerprint: compare retention pattern, integration window, system suitability, and acceptance criteria with a qualified reference batch.
• Mass spectrometry: report component-level ions, ionization conditions, tolerances, and interpretation. Do not describe one mass as confirmation of the whole fraction.
• Peak-area percentage: state the denominator and qualified fingerprint window. For a mixture, it cannot mean that one peak is the entire material.
• Total loading: a peptide- or protein-content assay may support total material loading, subject to method specificity and interference.
• Separate controls: sterility and endotoxin records answer microbiological questions; they do not establish chemical identity or activity.

This guide makes no Apex-specific assertion about what the current ESI-MS step establishes or how the current purity denominator is calculated; those first-party questions remain with the laboratory record. The HPLC guide, mass-spectrometry guide, and COA guide explain the general method boundaries. Current released records belong in the Lab Verified archive.

Storage and handling are separate from identity. Use the research storage guide and, where an approved laboratory protocol requires calculation support, the research reconstitution calculator and laboratory reconstitution guide. This article does not reproduce a procedure.

Evidence Strength and Unresolved Questions

Thymalin has no United States regulatory record: the FDA drug-application and labeling databases returned no result for the term when checked August 24, 2026. Papers from the originating group describe it as a drug preparation in its country of origin, but this guide asserts no registration number, date, or authority; the Russian State Register of Medicines was not programmatically queryable in that pass.

The longevity and bioregulator hub owns category-level comparison, while this guide owns single-material identity and evidence adjudication. The broader research-grade boundary guide explains why a research reagent cannot inherit claims from a drug or historical preparation.

Frequently Asked Questions

Research Use Disclaimer

Thymalin is discussed as a research-grade lyophilized reagent for in-vitro and preclinical research only. It is not a pharmaceutical product, is not for human or veterinary consumption, and is not presented as a treatment. This page provides no dosing, administration, preparation, or medical guidance.